CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas where it believes it has core strengths: building clinical adoption of molecular testing, supporting repeat testing workflows and generating evidence to support reimbursement. He said those priorities led the company to divest its lab products business, accelerate its AlloHeme pipeline program and pursue the acquisition of Naveris, a company focused on viral-mediated cancers.